When was Avanzanite founded?

Avanzanite was founded in 2021 and raised its 1st funding round 4 years after it was founded.

Where is Avanzanite located?

Avanzanite is headquartered in Amsterdam, Netherlands.

How many employees does Avanzanite have?

As of Aug 31, 2026, the latest employee count at Avanzanite is 93.

Is Avanzanite a funded company?

Avanzanite is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Nov 18, 2025.

When was the latest funding round of Avanzanite?

Avanzanite's latest funding was a $***** Series A round on Nov 18, 2025, with participation from 1 investor.

Where does Avanzanite rank among its competitors?

Avanzanite ranks 80th amongst 279 active competitors, of which 78 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Avanzanite, which secured $37.1M in Nov, 2025.

Who are the top competitors of Avanzanite?

Avanzanite's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Avanzanite secured the most recent funding round in November, 2025.

Avanzanite - 2026 Company Profile, Team, Funding & Competitors

Avanzanite is a series A company based in Amsterdam (Netherlands), founded in 2021 by Adam Andrzej Plich. It operates as a Developer of therapeutics to treat rare diseases. Avanzanite has raised $37.1M in funding. The company has 279 active competitors, including 78 funded and 96 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of therapeutics to treat rare diseases. The company focuses on the development of orphan medicine for the treatment of an ultra-rare ophthalmologic disease which includes Acanthamoeba Keratitis (AK) a devastating, highly resistant eye infection.

Website: avanzanite.com
Social
Email ID: *****@avanzanite.com
Phone Number: +31 **********

Key Metrics

Founded Year

2021

Location

Amsterdam, Netherlands

Stage

Series A

Total Funding

$37.1M in 1 round

Latest Funding Round

Series A, Nov 18, 2025, $*****

Investors

MVM

Ranked

80^th among 279 active competitors

Employee Count

93 as on Aug 31, 2026

Similar Companies

BridgeBio & 313 more

View Avanzanite's full profile

Avanzanite has raised a total funding of $37.1M over 1 round. Its latest funding round was a Series A round on Nov 18, 2025 for $*****. 1 investor participated in its latest round. Avanzanite has 1 institutional investor.

Here is the list of recent funding rounds of Avanzanite:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 18, 2025	9849515	Series A	8490397	9963993	8212391	6605284

Access funding benchmarks and valuations. Sign up today!

View details of Avanzanite's funding rounds and investors

The founders of Avanzanite is Adam Andrzej Plich.

Here are the details of Avanzanite's key team members:

Adam Andrzej Plich: Co-Founder and Board Member of Avanzanite.
Contact Info: 1 email address

View details of Avanzanite's Founder profiles and Board Members

Avanzanite's employee count trend

Avanzanite has 93 employees as of Aug 26. Here is Avanzanite's employee count trend over the years:

Uncover Avanzanite's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avanzanite include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Avanzanite, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
80th	Avanzanite 2021, Amsterdam (Netherlands), Series A	Developer of therapeutics to treat rare diseases	$37.1M	MVM	50/100